The purpose of this research study is to test and adapt new techniques for performing magnetic resonance imaging (MRI). MRI provides pictures of the inside of the body and information about chemicals the body makes. Here are some examples of what we hope to accomplish:

1. Adapt MRI techniques used at other institutions for use on CHOP MRI scanners

2. Increase the amount of information learned from each MRI image

The research sequences involve changing the settings of the magnetic resonance scanner. By research sequences we mean that they are not approved by the US Food and Drug Administration (FDA) for clinical use. The data we obtain will help the FDA evaluate whether or not they can eventually approve the sequences for clinical use.

We are seeking to enroll healthy volunteers, 18 years of age and above. Pregnant females excluded for safety purposes.

The purpose of this study is to identify and engage young black or hispanic/latino men (male sex at birth, but gender identity male, transfemale, or gender nonconforming) (YBLMSM/transwomen) in Philadelphia, PA, Baltimore, MD and Washington, DC in HIV and substance use prevention using a new Mobile-enhanced Engagement intervention (app that reminds you to take your meds, reminds you of your medical appointments, etc.). There are three different parts to this study: 1) respondent driven sampling (RDS); 2) Randomized Control Trial (RCT): MEI vs Standard of Care for HIV+ youth; and 3) PrEP RCT: Pre Exposure Prophylaxis - Mobile-enhanced Engagement Intervention (PrEP-MEI) vs. Standard PrEP referral;. It is possible to participate in only the RDS, the RDS and the AIM 3 PrEP RCT, or the RDS and AIM 2 RCT studies.

The RDS study involves 2 study visits lasting up to 1 month of participation where participants will be asked to complete an optional rapid HIV test (oral or fingerstick) or viral load testing (blood draw), web-based survey (on past sexual and HIV experiences), recruit your peers to participate in the study, and complete a post-recruitment survey. YBLMSM/transwomen and cisgender females 15-24 years may participate in RDS, but the following study portions are only for YBLMSM/transwomen:

People who successfully complete the RDS portion of the study may be asked to participate in an additional study visit of an audio-recorded focus group or interview.

The RCT study involves 6 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different HIV supportive interventions: 1) HIV case management with a Mobile-enhanced Engagement Intervention (MEI), or 2) standard of care HIV case management where a case manager will remind you of medical appointments. If you are assigned to the first group (MEI), you will be asked to use the MEI mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody and Viral load testing (blood draw), urine drug testing, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.

The PrEP RCT study involves 5 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different PrEP and substance use supportive interventions: 1) PrEP case management with a Mobile-enhanced Engagement Intervention (MEI-PrEP), or 2) standard PrEP referrals to services. If you are assigned to the first group (MEI-PrEP), you will be asked to use the MEI-PrEP mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody (blood draw or 2 rapid OraQuick tests in place of serologic 4th generation testing when 4th generation testing is not available) and Viral load testing (blood draw), urine drug testing, use the MEI-PrEP mobile app or web-browser version of the app, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.

We are currently enrolling adolescents ages 15-21 of South Asian ancestry, African American ancestry, and European American or "White" ancestry. This study is looking to better understand ancestry related differences in risks for developing cardiovascular disease and type 2 diabetes. The study involves 2 visits to the CHOP Main Hospital in Philadelphia, and participants will be compensated for their efforts.

The purpose of this registry is to study the long-term effects and safety of Abatacept(Orencia) as used for the treatment of Juvenile Idiopathic Arthritis(JIA). JIA patients that are currently taking Abatacept may be eligible to participate in this study.

The purpose of this study is to assess deficits in movement and coordination in children with cerebral palsy (CP) and without. Children with CP have trouble coordinating their muscles while moving. Few options exist to measure muscle control. This new test will measure muscle control in children with and without CP and help guide future treatment plans.

In this study, we are developing new magnetic resonance imaging (MRI) and ultrasound methods to determine if it is effective in diagnosing complication in kidney transplant patients. Participants in this study will involve patients that have had a kidney transplant and are scheduled for a kidney biopsy. The study will also involve a comparison group of healthy individuals that have no history of kidney conditions. Study procedures will include a review of medical history and medications, MRI scan and ultrasound of the abdomen and blood/ urine test.

This is an intergrated study of patients with congenital glycosylation disorder, including genetic conditions in the synthesis of glycoconjugates (congenital disorder of glycosyaltion), degradation of glycoconjugates (majority of lysosomal storage conditions), as well as the metabolism of glycoconjugates (such as certain inborn errors of metabolism that involved in nucleitide sugar metabolism, such as galactosemia, fructose intolarance, or certain glycogen storage conditions). Study methods includes glycomics analysis of body fluid or cells or tissues from patients, relevant metabolomics and genomics analysis.

We are looking at how infants and young children breathe in different positions. This will help us understand how children with different types of lung hypoplasia breathe and how the lung changes and grows. To do this, we will measure regional lung ventilation by electrical impedance tomography (EIT) in three positions: lying on the back, right- and left-side in children with pulmonary hypoplasia and in healthy children without lung disease. EIT has been well established as a safe, non-invasive, radiation free method of assessing regional lung ventilation. There is no compensation available for this study.

The purpose of this research study is to help us understand how well tofacitinib works as a treatment for ulcerative colitis or indeterminate colitis in pediatric patients. We are looking to enroll, males or females ages 6 to 21 years old with a diagnosis of ulcerative colitis or indeterminate colitis who have started tofacitinib therapy prescribed by their primary gastroenterologist within the past 2 weeks or will be starting tofafacitinib within 1 month.

This clinical trial study uses a modified adeno-associated virus (AAV) to carry the human factor VIII gene to the liver. In the liver is where factor VIII protein is made. The study product, SPK-8011, is available only to participants in this research study. This product has not been approved yet for use in the general public. This will be the first hemophilia A gene transfer research study done in the United States. To learn more about the benefits and risks related to this study, please contact Dr. Lindsey George at (267) 425-0132. In order to participate in this study, you must be male, 18 years or older, have hemophilia A with FVIII activity levels less or equal to 2%, a history of bleeding that requires prophylaxis or on demand therapy, and no history of inhibitor to factor VIII. This study requires a number of visits over the course of 12 months. All costs related to participation in the study will either be covered or reimbursed by the Sponsor of the study, Spark Therapeutics, and participants will be compensated for their time.